about
Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes MellitusCardiovascular outcomes in trials of oral diabetes medications: a systematic reviewNIH working group report-using genomic information to guide weight management: From universal to precision treatmentAre physicians prepared for whole genome sequencing? a qualitative analysisEfficacy and safety of ginsam, a vinegar extract from Panax ginseng, in type 2 diabetic patients: Results of a double-blind, placebo-controlled study.Metabolite traits and genetic risk provide complementary information for the prediction of future type 2 diabetes.Despite Underestimated Familial Risk by Self-Report, Family History Correlates with Perceived Risk and Worry about Chronic Diseases Such as Coronary Heart Disease and Diabetes.Do physicians think genomic medicine will be useful for patient care?Patients' perceived utility of whole-genome sequencing for their healthcare: findings from the MedSeq project.Impact of literacy and numeracy on motivation for behavior change after diabetes genetic risk testing.Comment on: Alssema et al. One risk assessment tool for cardiovascular disease, type 2 diabetes, and chronic kidney disease. Diabetes Care 2012; 35:741-748.Can genetic information change patient behavior to reduce Type 2 diabetes risk?Yield and bias in defining a cohort study baseline from electronic health record data.When bins blur: Patient perspectives on categories of results from clinical whole genome sequencing.Short-term costs of integrating whole-genome sequencing into primary care and cardiology settings: a pilot randomized trial.Comparison of regional body composition and its relation with cardiometabolic risk between BMI-matched young and old subjects.Appropriateness: A Key to Enabling the Use of Genomics in Clinical Practice?Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite studyThe Integrating Pharmacogenetics in Clinical Care (I-PICC) Study: Protocol for a point-of-care randomized controlled trial of statin pharmacogenetics in primary careA phenotyping algorithm to identify acute ischemic stroke accurately from a national biobank: the Million Veteran ProgramDiabetes Mellitus-Related All-Cause and Cardiovascular Mortality in a National Cohort of AdultsResponse to comment on Vassy et al. polygenic type 2 diabetes prediction at the limit of common variant detection. Diabetes 2014;63:2172-2182Toward greater understanding of patient decision-making around genome sequencingPharmacogenetic testing in the Veterans Health Administration (VHA): policy recommendations from the VHA Clinical Pharmacogenetics SubcommitteeAssociation Between Early Hypertension Control and Cardiovascular Disease Incidence in Veterans With DiabetesReconciling Opportunistic and Population Screening in Clinical GenomicsResponse to Gammal et alImpact of SLCO1B1 Pharmacogenetic Testing on Patient and Healthcare Outcomes: A Systematic ReviewCorrection: Secondary findings from clinical genomic sequencing: prevalence, patient perspectives, family history assessment, and health-care costs from a multisite studyGenomic testing is best integrated into clinical practice when it is actionableFried food consumption and risk of coronary artery disease: The Million Veteran ProgramRandom plasma glucose predicts the diagnosis of diabetesOmega-3 supplement use, fish intake, and risk of non-fatal coronary artery disease and ischemic stroke in the Million Veteran ProgramThe Responsibility to Recontact Research Participants after Reinterpretation of Genetic and Genomic Research ResultsEstimated Filtration: The Continued Need for Expert Classification of Genetic VariantsSmoking-by-genotype interaction in type 2 diabetes risk and fasting glucosePalbociclib and Fulvestrant in Breast Cancer
P50
Q22241140-58855953-8CD4-4F8B-8E2A-BDEF11D90A2FQ22253058-DC7825C1-ED6E-4D1D-92F6-B4B6F9A9FFE2Q26773982-EDBFDEFE-E168-4277-803E-F1448F9457AEQ30203352-66A44632-B87A-421B-A4D8-CE00013CD92DQ33585792-72FB3480-67A2-402E-B479-FCFE7FE44DACQ34073453-C13ADE5C-2E04-4E32-B267-16F890006D25Q34577672-9B9C325B-FBB0-4529-B4D8-B15B04F3F7C7Q35827874-BE116156-D004-44DE-B8A9-3EFE9319889AQ36724985-EA9CBF38-3982-44CF-B72C-D27262CD526AQ36931432-8D9D03C7-AE54-4924-85E8-47AEED2998D0Q42326642-36959777-0C2E-4064-9CD5-EDF250C778AAQ42791207-F6769D68-DB6D-4A60-A99B-DC047B386256Q47202959-90E85EFB-86AB-4F5A-BE1C-03CEBE68BA0EQ47294616-3F9F3A69-2429-4643-BF95-923B87110FD1Q51736658-D46FCFD3-AF65-4D12-92CA-19B47B641019Q53367152-410B9EAC-7CCA-4A3E-B888-38631500C9D9Q54967552-B7CED9D1-6A2D-44E2-8692-7BD3D07130CDQ56980485-02C2A6F3-1CDD-4AA6-8273-9EF5937781DAQ58118140-9967FA96-3FF7-4473-A2CC-B02FC61C01AFQ58694684-DF107237-331A-4ACA-81B9-467410B928C9Q64242008-6EE8C4CC-F4D5-452A-B252-70288C3182CDQ88150413-2524AFAB-7139-4794-8C03-1A00AE4B0C8CQ88528819-24DE1F2B-000E-4241-9F2F-070F1A0BA172Q88955602-58E0751D-CD45-4777-BC8A-76CA495F00E5Q90082894-B55B6ABA-EDF2-4237-ACCA-2C4B0C69CFB0Q90902087-4B321CB2-9F08-4592-BABB-16EAB002B44CQ91011006-ADB55929-FC19-436A-89BC-FC274C512385Q91102477-DFAEF7E8-A2A4-4241-AB0B-B952B7EAA1C4Q91168949-56C6616A-582C-4FB4-877E-F3381C4A8F3AQ91649483-6DA298A6-640A-4CF8-9661-12B42E1773A7Q91675720-5C2F630D-3988-4C89-B28E-620E1522BA82Q92021650-A8E1B20B-724B-4781-8B2F-62E660BF9476Q92633824-19B3B77E-0149-4853-9093-051A126971D9Q92878039-024AB20E-8F7C-4CF0-BC70-1023C60123DDQ93375408-BCEDCBDD-3AC6-4F5A-BE73-4CE2A3AB4D5DQ94606219-D4719E8F-A437-41DB-BF31-6B34D2A52FBAQ95764275-68BC772E-3FFC-4351-B42D-52C4AB22FEC6
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Jason Vassy
@en
Jason Vassy
@nl
type
label
Jason Vassy
@en
Jason Vassy
@nl
prefLabel
Jason Vassy
@en
Jason Vassy
@nl
P31
P496
0000-0001-6113-5564